• Something wrong with this record ?

TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations

S. Gupta, P. Argani, AA. Jungbluth, YB. Chen, SK. Tickoo, SW. Fine, A. Gopalan, HA. Al-Ahmadie, SJ. Sirintrapun, A. Sanchez, AA. Hakimi, T. Mcfarlane, PA. Salazar, SR. Williamson, SL. Skala, R. Mehra, O. Hes, CR. Antonescu, M. Ladanyi, ME....

. 2019 ; 43 (11) : 1445-1461. [pub] -

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20023505

Grant support
P30 CA008748 NCI NIH HHS - United States
T32 CA082088 NCI NIH HHS - United States

TFEB is overexpressed in TFEB-rearranged renal cell carcinomas as well as in renal tumors with amplifications of TFEB at 6p21.1. As recent literature suggests that renal tumors with 6p21.1 amplification behave more aggressively than those with rearrangements of TFEB, we compared relative TFEB gene expression in these tumors. This study included 37 TFEB-altered tumors: 15 6p21.1-amplified and 22 TFEB-rearranged (including 5 cases from The Cancer Genome Atlas data set). TFEB status was verified using a combination of fluorescent in situ hybridization (n=27) or comprehensive molecular profiling (n=13) and digital droplet polymerase chain reaction was used to quantify TFEB mRNA expression in 6p21.1-amplified (n=9) and TFEB-rearranged renal tumors (n=19). These results were correlated with TFEB immunohistochemistry. TFEB-altered tumors had higher TFEB expression when normalized to B2M (mean: 168.9%, n=28), compared with non-TFEB-altered controls (mean: 7%, n=18, P=0.005). Interestingly, TFEB expression in tumors with rearrangements (mean: 224.7%, n=19) was higher compared with 6p21.1-amplified tumors (mean: 51.2%, n=9; P=0.06). Of note, classic biphasic morphology was only seen in TFEB-rearranged tumors and when present correlated with 6.8-fold higher TFEB expression (P=0.00004). Our results suggest that 6p21.1 amplified renal tumors show increased TFEB gene expression but not as much as t(6;11) renal tumors. These findings correlate with the less consistent/diffuse expression of downstream markers of TFEB activation (cathepsin K, melan A, HMB45) seen in the amplified neoplasms. This suggests that the aggressive biological behavior of 6p21.1 amplified renal tumors might be secondary to other genes at the 6p21.1 locus that are co-amplified, such as VEGFA and CCND3, or other genetic alterations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023505
003      
CZ-PrNML
005      
20201214130223.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PAS.0000000000001307 $2 doi
035    __
$a (PubMed)31600176
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gupta, Sounak $u Departments of Pathology.
245    10
$a TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations / $c S. Gupta, P. Argani, AA. Jungbluth, YB. Chen, SK. Tickoo, SW. Fine, A. Gopalan, HA. Al-Ahmadie, SJ. Sirintrapun, A. Sanchez, AA. Hakimi, T. Mcfarlane, PA. Salazar, SR. Williamson, SL. Skala, R. Mehra, O. Hes, CR. Antonescu, M. Ladanyi, ME. Arcila, VE. Reuter,
520    9_
$a TFEB is overexpressed in TFEB-rearranged renal cell carcinomas as well as in renal tumors with amplifications of TFEB at 6p21.1. As recent literature suggests that renal tumors with 6p21.1 amplification behave more aggressively than those with rearrangements of TFEB, we compared relative TFEB gene expression in these tumors. This study included 37 TFEB-altered tumors: 15 6p21.1-amplified and 22 TFEB-rearranged (including 5 cases from The Cancer Genome Atlas data set). TFEB status was verified using a combination of fluorescent in situ hybridization (n=27) or comprehensive molecular profiling (n=13) and digital droplet polymerase chain reaction was used to quantify TFEB mRNA expression in 6p21.1-amplified (n=9) and TFEB-rearranged renal tumors (n=19). These results were correlated with TFEB immunohistochemistry. TFEB-altered tumors had higher TFEB expression when normalized to B2M (mean: 168.9%, n=28), compared with non-TFEB-altered controls (mean: 7%, n=18, P=0.005). Interestingly, TFEB expression in tumors with rearrangements (mean: 224.7%, n=19) was higher compared with 6p21.1-amplified tumors (mean: 51.2%, n=9; P=0.06). Of note, classic biphasic morphology was only seen in TFEB-rearranged tumors and when present correlated with 6.8-fold higher TFEB expression (P=0.00004). Our results suggest that 6p21.1 amplified renal tumors show increased TFEB gene expression but not as much as t(6;11) renal tumors. These findings correlate with the less consistent/diffuse expression of downstream markers of TFEB activation (cathepsin K, melan A, HMB45) seen in the amplified neoplasms. This suggests that the aggressive biological behavior of 6p21.1 amplified renal tumors might be secondary to other genes at the 6p21.1 locus that are co-amplified, such as VEGFA and CCND3, or other genetic alterations.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a transkripční faktory BHLH-Zip $x metabolismus $7 D051778
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a karcinom z renálních buněk $x diagnóza $x metabolismus $x patologie $7 D002292
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a nádory ledvin $x diagnóza $x metabolismus $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
655    _2
$a časopisecké články $7 D016428
700    1_
$a Argani, Pedram $u Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD.
700    1_
$a Jungbluth, Achim A $u Departments of Pathology.
700    1_
$a Chen, Ying-Bei $u Departments of Pathology.
700    1_
$a Tickoo, Satish K $u Departments of Pathology.
700    1_
$a Fine, Samson W $u Departments of Pathology.
700    1_
$a Gopalan, Anuradha $u Departments of Pathology.
700    1_
$a Al-Ahmadie, Hikmat A $u Departments of Pathology.
700    1_
$a Sirintrapun, Sahussapont J $u Departments of Pathology.
700    1_
$a Sanchez, Alejandro $u Surgery, Urology Service. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
700    1_
$a Hakimi, Abraham Ari $u Surgery, Urology Service. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
700    1_
$a Mcfarlane, Tiffany $u Departments of Pathology.
700    1_
$a Salazar, Paulo A $u Departments of Pathology.
700    1_
$a Williamson, Sean R $u Department of Pathology & Laboratory Medicine, Henry Ford Health System, Detroit.
700    1_
$a Skala, Stephanie L $u Department of Pathology, University of Michigan Health System, Ann Arbor, MI.
700    1_
$a Mehra, Rohit $u Department of Pathology, University of Michigan Health System, Ann Arbor, MI.
700    1_
$a Hes, Ondrej $u Department of Pathology, University Hospital Plzeň, Charles University, Pilsen, Czech Republic.
700    1_
$a Antonescu, Cristina R $u Departments of Pathology.
700    1_
$a Ladanyi, Marc $u Departments of Pathology.
700    1_
$a Arcila, Maria E $u Departments of Pathology.
700    1_
$a Reuter, Victor E $u Departments of Pathology.
773    0_
$w MED00000304 $t The American journal of surgical pathology $x 1532-0979 $g Roč. 43, č. 11 (2019), s. 1445-1461
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31600176 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130222 $b ABA008
999    __
$a ok $b bmc $g 1595824 $s 1114181
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 43 $c 11 $d 1445-1461 $e - $i 1532-0979 $m The American journal of surgical pathology $n Am J Surg Pathol $x MED00000304
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
GRA    __
$a T32 CA082088 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options